Key result
PCI with everolimus-eluting stents yields higher MACE rates than CABG in multivessel CAD.
Why the study?
Does PCI with everolimus-eluting stents improve major adverse cardiovascular events in patients with multivessel coronary artery disease compared to CABG?
Does PCI with everolimus-eluting stents improve major adverse cardiovascular events in patients with multivessel coronary artery disease compared to CABG?
In patients with multivessel coronary artery disease, CABG is associated with a lower rate of major adverse cardiovascular events compared to PCI with everolimus-eluting stents.
Prefer CABG over everolimus-eluting PCI in multivessel CAD; challenges consensus on PCI equivalence.
Among patients with multivessel coronary artery disease, the rate of major adverse cardiovascular events was higher among those who had undergone PCI with the use of everolimus-eluting stents than among those who had undergone CABG. (Funded by CardioVascular Research Foundation and others; BEST ClinicalTrials.gov number, NCT00997828.).
No takes yet. Share an insight, caveat, or question.
Park et al. (2015) studied this question. In patients with multivessel coronary artery disease, PCI using everolimus-eluting stents led to a higher rate of major adverse cardiovascular events compared to CABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: